Optimal role of temozolomide in the treatment of malignant gliomas

Roger Stupp*, Martin J. van den Bent, Monika E. Hegi

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

163 Scopus citations


Temozolomide (TMZ) is an alkylating agent that was approved for anaplastic astrocytoma and glioblastoma. Its role in the treatment of recurrent disease has been confirmed, and more importantly, alternative treatment schedules and combination regimens have been developed. A recent phase III trial has demonstrated a survival advantage for concomitant TMZ administration with radiotherapy in patients with newly diagnosed glioblastoma. Molecular studies suggest a strong predictive role of the DNA repair enzyme O6-methyl-guanine-DNA-methyl-transferase (MGMT) and outcome of TMZ-based chemotherapy. This review summarizes the current knowledge, highlights approved and nonapproved indications, and describes molecular studies that may allow us to identify the patients most likely to benefit from this treatment.

Original languageEnglish (US)
Pages (from-to)198-206
Number of pages9
JournalCurrent neurology and neuroscience reports
Issue number3
StatePublished - May 2005

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Optimal role of temozolomide in the treatment of malignant gliomas'. Together they form a unique fingerprint.

Cite this